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Essentials
• Preimplantation genetic diagnosis (PGD) of severe hemophilia A relies on linkage analysis.
• Simultaneous multi-marker screening can simplify selection of informative markers in a couple.
• We developed a single-tube tetradecaplex panel of polymorphic markers for hemophilia A PGD use.
• Informative markers can be used for linkage analysis alone or combined with mutation detection.
Summary.
Background: It is currently not possible to perform single-cell preimplantation genetic diagnosis (PGD) to directly detect the common inversion mutations of the factor VIII (F8) gene responsible for severe hemophilia A (HEMA). As such, PGD for such inversion carriers relies on indirect analysis of linked polymorphic markers. Objectives: To simplify linkage-based PGD of HEMA, we aimed to develop a panel of highly polymorphic microsatellite markers located near the F8 gene that could be simultaneously genotyped in a multiplex-PCR reaction. Methods: We assessed the polymorphism of various microsatellite markers located ≤ 1 Mb from F8 in 177 female subjects. Highly polymorphic markers were selected for co-amplification with the AMELX/Y indel dimorphism in a single-tube reaction. Results: Thirteen microsatellite markers located within 0.6 Mb of F8 were successfully co-amplified with AMELX/Y in a single-tube reaction. Observed heterozygosities of component markers ranged from 0.43 to 0.84, and 70-80% of individuals were heterozygous for ≥ 5 markers. The tetradecaplex panel successfully identified fully informative markers in a couple interested in PGD for HEMA because of an intragenic F8 point mutation, with haplotype phasing established through a carrier daughter. In-vitro fertilization (IVF)-PGD involved single-tube co-amplification of fully informative markers with AMELX/Y and the mutationcontaining F8 amplicon, followed by microsatellite analysis and amplicon mutation-site minisequencing analysis. Conclusions: The single-tube multiplex-PCR format of this highly polymorphic microsatellite marker panel simplifies identification and selection of informative markers for linkage-based PGD of HEMA. Informative
Introduction
Hemophilia A (HEMA, OMIM: 306700) is an X-linked, recessively inherited bleeding disorder characterized by deficiency of coagulation factor VIII (FVIII) clotting activity, which results from mutations in the factor VIII (F8) gene located at chromosome Xq28 [1] . The disease affects approximately one in 5000 men worldwide [2] . Severe HEMA, where FVIII clotting activity is < 1%, exhibits spontaneous joint or deep-muscle bleeding. The intron 22 and intron 1 inversion mutations together account for~50% of severe HEMA cases [3, 4] , whereas more than 2000 different mutations have been identified in the remaining cases [5, 6] . The paracentric inversion mutations can be detected using special long-distance PCR (LD-PCR) methods, which unfortunately are not adaptable to single-cell preimplantation genetic diagnosis (PGD) because of the requirement for large amounts of input DNA template (250 ng) [7] . The heterogeneity of F8 point mutations also necessitates assay customization to detect each different mutation. Although HEMA is an X-linked recessive disorder, PGD by female sex selection is unsatisfactory because (i)~10% of female carriers exhibit the disease and experience some abnormal bleeding, probably as a result of non-random X-inactivation [2, 8] , and (ii) each excluded male embryo has a 50% chance of being unaffected. Under these circumstances, linkage analysis of informative markers offers an alternative means for PGD of HEMA. This indirect test can be performed either as a standalone assay when there is an affected male in the family to establish disease allele phase, or in combination with direct detection of a specific point mutation. Not only are the linked markers useful in tracking the inheritance of the mutant allele, they also serve to monitor the presence of exogenous DNA contaminations and allele drop-out (ADO), in the process increasing confidence in the PGD results [9] . Microsatellite markers, also referred to as short tandem repeats (STRs), have been widely used in linkage analysis as they are highly polymorphic and widespread within the human genome. A list of STRs located in and around the F8 gene has been reported previously [10] , some of which have been multiplexed in small panels [9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, a majority of these STRs have not been tested experimentally and their heterozygosity and polymorphism indices are unknown. Furthermore, existing multiplex STR panels contain no more than seven markers with or without Amelogenin X and Y (AMELX/Y) for gender determination [13, 16, 21] . The number of STR markers available and the information that can be obtained from these markers are of great importance for the purposes of linkage-based disease diagnosis. In the case of HEMA, at least one informative intragenic marker or one informative extragenic marker close to either end of F8 is required for accurate prenatal diagnosis or PGD [2, 9] . Currently, informative markers must be customized for each couple undergoing PGD. Having a large panel of highly polymorphic markers will greatly increase the odds of identifying two or more informative markers in any couple. We therefore evaluated numerous STRs located in and around the F8 gene, and developed a multiplex panel consisting of 13 highly polymorphic STR markers located within 0.6 Mb of F8 (DXS1073, REN90682, REN90833, F8Int25.2, F8Int22, F8Int21, F8Int13.2, F8Int1, stSG604486, HEMA154130.5, TMLHEInt2, TMLHEInt1.1 and HEMA154498.9), together with the AMELX/Y. These markers can be co-amplified with a specific mutation-site fragment, and an aliquot of the multiplex PCR product can be subsequently used for mutation detection by minisequencing. We have successfully applied this combined mutation detection and linkage analysis strategy to a clinical in-vitro fertilization (IVF)-PGD case.
Materials and methods

DNA samples
Genomic DNA was extracted from 24 lymphoblastoid cell lines purchased from Coriell Cell Repositories (CCR, Camden, NJ, USA) and from 128 unrelated and anonymized cord bloods of Chinese babies born at the National University Hospital. The Caucasian (HD100CAU) Human Variation DNA panel was purchased from CCR. DNA was used for initial genotyping analysis of potential microsatellite markers, multiplex panel optimization or determining heterozygosity values.
This study was approved by the Institutional Review Board of the National University of Singapore (07-123E and 13-309E).
Microsatellite marker selection and primer design
Twenty-eight microsatellite markers were selected from a previously reported Xq28 STR list [10] Table 1 footnotes). Thermal cycling was identical to the PCR step, except that five cycles were performed. Markers with the highest heterozygosity values were selected for co-amplification in a tetradecaplex PCR panel. Amplification was performed in a 20-lL reaction consisting of 10 ng genomic DNA, 19 Qiagen Multiplex Mastermix (Qiagen), 0.759 Q-Solution (Qiagen) and 0.1-0.6 lM of each unlabeled primer (Table 1) . Thermal cycling involved an initial 15-min polymerase activation at 95°C, followed by 30 cycles of 94°C for 30 s, 60°C for 90 s and 72°C for 60 s, and ending with a final extension at 60°C for 30 min. A 2-lL aliquot of multiplex PCR product was used as a template for extension labeling in a 20-lL reaction using 0.1 or 0.2 lM of 6-Fam-labeled M13-1 primer, Hex-labeled M13-2 primer and Ned-labeled M13-3 primer. Thermal cycling was identical to the multiplex PCR step, except that 10 cycles were performed and Q-solution was omitted. The optimized multiplex marker panel was used to genotype 128 anonymous Chinese and 49 anonymous Caucasian DNA samples to obtain more precise heterozygosity values for each of the component markers. 
IVF-PGD of F8 c.5881T>C mutation
A couple requested IVF-PGD in order to avoid HEMA because the wife carries a c.5881T>C mutation in exon 18 of F8. A PCR-minisequencing assay was developed to detect the point mutation. To confirm the presence of heterozygous c.5881T>C in the wife and carrier daughter but not in the husband, PCR amplification was performed as described for the individual marker amplification, except that 2.5 U HotStar Taq, denaturation temperature of 98°C and 0.2 lM of exon 18 forward and reverse primers were used. For minisequencing, a 2.5-lL aliquot of the amplification product was incubated with 10 U exonuclease I (GE Healthcare, Chicago, IL, USA) and 1 U shrimp alkaline phosphatase (GE Healthcare) at 37°C for 45 min in a volume of 4.5 lL, and then heated at 80°C for 15 min. To 1 lL of the treated PCR product, 0.5 lL of SNaPshot Ò Multiplex Kit (ThermoFisher Scientific, Waltham, MA, USA) and 0.6 lM of forward and reverse minisequencing primers were added (Table 1) , and the mixture was subjected to cycle minisequencing consisting of 35 cycles of 96°C for 10 s, 50°C for 5 s and 60°C for 30 s. One unit of shrimp alkaline phosphatase was added to the minisequencing product and incubated at 37°C for 1 h followed by a 75°C incubation for 15 minutes. In parallel, the multiplex marker panel was genotyped on the parent and child trio to identify the informative markers and establish the maternal disease and non-disease haplotypes.
For the clinical IVF-PGD case, each isolated blastomere was lysed by adding 2 lL of 0.4 M potassium hydroxide (Sigma-Aldrich, St. Louis, MO, USA), heated at 65°C for 10 min, rapidly cooled to 4°C, and neutralized using 2 lL of 0.4 M Tricine (Sigma-Aldrich). The F8 exon 18 fragment was co-amplified with all fully informative STR markers and the AMELX/Y dimorphism directly from each lysed and neutralized blastomere. Amplification conditions were as described for the tetradecaplex PCR assay, except that the final volume was 50 lL, all primer concentrations were at 0.2 lM, 40 cycles were used and a 6-s auto-extension was added to each cycle. A 2-lL aliquot of multiplex amplification product was removed for extension labeling, as described for the tetradecaplex PCR product from genomic DNA, except that 0.1 lM each of the reverse primers for REN90833 and stSG604486 were included and eight cycles were used. A separate 2.5-lL aliquot of multiplex amplification product was used for minisequencing of the F8 c.5881T>C mutation exactly as described above.
Capillary electrophoresis and analysis A 1-lL aliquot of extension labeling product was mixed with 9 ll of Hi-Di ™ formamide (Applied Biosystems, Foster City, CA, USA) and 0.3 lL of GeneScan ™ 500 ROX ™ dye size standard (Applied Biosystems). A 1-lL aliquot of the cleaned-up minisequencing product was mixed with 9 lL of Hi-Di ™ formamide and 0. 
Data analysis
Expected heterozygosity (H e ) [23] and observed heterozygosity (H o ) [24] of the 13 microsatellite markers were calculated using Microsoft Excel and Cervus software [25] . Hardy-Weinberg equilibrium was estimated using GenePop software [26] . Table 1 and the positions of all 13 STR markers relative to F8 are shown in Fig. 1(A) . All markers lie within 0.6 Mb of F8. Representative multiplex PCR electropherograms from a female (GM16216) and male (GM04866) sample are shown in Fig. 1(B) . Each marker can be easily distinguished by its allele size range, peak pattern and peak color.
Results
Filtering of microsatellite markers
Heterozygosity and polymorphism assessment (Table 1) . Between four and 16 alleles were observed for each marker (Fig. S1 ). All samples were heterozygous for at least one marker ( Fig. 2A) . At least one intragenic marker was heterozygous in 103/128 Chinese samples (~80%) and 41/ 49 (~84%) Caucasian samples (Fig. 2B) . Among the 13 markers, HEMA154498.9 is the most informative, with H o of 0.84 and 0.78 in the Chinese and Caucasian populations, respectively. Overall, the panel was 100% informative for all the samples that were genotyped, with at least one heterozygous marker in every sample ( Fig. 2A) . All markers in the STR panel lie well within 1 Mb of the F8 gene. Therefore, the likelihood of recombination between any marker and any F8 mutation, including the common paracentric inversions, is expected to be < 1%. When using extragenic markers, ideally at least one informative marker is available on each side of the mutation, to rule out even the rare marker-mutation recombination event.
If we assume that a mutation is present between markers F8Int13.2 and F8Int21, then~98% (126/128) and~82% (40/49) of Chinese and Caucasian samples, respectively, would be heterozygous for at least one marker upstream and one downstream of that mutation (Fig. 2C, 2D) . It is therefore likely that the tetradecaplex marker panel has sufficient ability to provide information and marker redundancy to be useful for a majority of families requesting PGD for HEMA, minimizing the need to identify additional markers, at least in the Chinese and Caucasian populations.
IVF-PGD cycle
In this couple, the wife is heterozygous for the F8 c.5881 T>C mutation in exon 18 (Fig. 3A) . Using the tetradecaplex PCR panel, four markers (REN90833, stSG604486, HEMA154130.5 and TMLHEInt2) were found to be fully informative and a fifth marker (DXS1073) was partially informative (Fig. 3B, 3C) . Validation of the fully informative markers was performed on 60 single cells from the wife. Successful amplification was observed for all markers in all cells and the ADO rate of the four markers ranged from 3.3% to 10%, complying with the European Society of Human Reproduction and Embryology PGD consortium's recommendations [9] . Based on these ADO rates, at least three informative markers should be used to achieve a 99% diagnostic confidence [9] . To maximize disease-allele phasing accuracy as well as ADO and marker recombination detection sensitivities, all four fully informative STR markers were co-amplified together with AMELX/Y and the mutation-containing F8 exon 18 amplicon for the IVF-PGD cycle. Eleven oocytes were recovered after ovarian stimulation, of which six matured sufficiently and were fertilized after intracytoplasmic sperm injection. Five embryos cleaved sufficiently for embryo biopsy on day three. Two blastomeres were biopsied from each of four embryos and one blastomere was removed from the fifth embryo. All blastomeres were analyzed separately. All nine blastomeres amplified successfully and produced analyzable results for all five embryos. No exogenous DNA contamination was detected in any of the reactions. ADO was observed for markers REN90833, stSG604486 and TMLHEInt2 in one blastomere of embryo 4 (data not shown). Nonetheless, unambiguous haplotype phasing of the normal and mutant chromosomes could be established, and this was confirmed by the haplotype phasing of the second blastomere from embryo 4, whereby no ADO occurred. In embryo 2, only paternal alleles were observed for the markers, although only the AMELX but not the AMELY amplicon was observed, suggesting that the embryo is chromosomally abnormal.
Direct mutation analysis by subsequent minisequencing revealed the absence of the mutant 'T' allele in embryos 1, 2, 3 and 5, indicative of an unaffected genotype. Both normal and mutant alleles were observed in embryo 4, indicating a carrier genotype (Fig. 4A) . The flanking marker haplotypes were also consistent with the mutation detection results (Fig. 4B and 4C ). Except for embryo 5, whose results were generated from only one blastomere, the blastomere pairs of the other embryos showed concordant results in their mutation genotypes and flanking marker haplotypes (data not shown). Embryos 3 and 5 were subsequently arrested in culture and did not progress to blastocyst stage. Embryos 1 and 4, diagnosed as an unaffected male and carrier female, respectively, were transferred, which, however, did not result in a pregnancy.
Discussion
Approximately 50% of severe HEMA is caused by large paracentric inversions mediated by the F8 gene intron 1-sequence and intron 22-sequence homologies to more distally located sequences. These inversions cannot be detected directly using current single-cell PGD methods, and indirect mutation detection by linkage analysis of polymorphic markers is the only option. The remaining HEMA cases are caused by private family-specific mutations, which would also benefit from complementary analysis of linked polymorphic markers to increase diagnostic accuracy. Therefore, linkage analysis, either as a standalone assay or as a complement to direct mutation detection, plays an important role in PGD of HEMA.
The proximity of and the information that can be obtained from markers are important considerations when used in linkage analysis. In order to maximize the possibility of detecting informative markers and simplify the PGD of HEMA, we developed a multiplex panel of 13 highly polymorphic STR markers that lie either within or < 600 kb upstream or downstream of the F8 gene. The panel also includes the AMELX/Y dimorphism for gender determination. Of the 13 STR markers, 11 have been studied previously as smaller panels in several populations [9, 11, 13, 14, [16] [17] [18] [19] 27] . The remaining two markers, TMLHEInt2 and HEMA154498.9, are being investigated for the first time and they are highly polymorphic. As intragenic markers are of particular value when mutations are not identified or cannot be detected at the single-cell level, five previously reported intragenic markers were included in the panel. Although they are only moderately polymorphic, when used in combination they should be able to determine the carrier status in~80% of the affected families according to the statement by the UK Haemophilia Center Doctors' Organization (UKHCDO) [2] . Our observation of at least one informative intragenic marker in~80% of the samples tested is in agreement with this report. UKHCDO recommends that only intragenic markers should be considered for linkage analysis; however, these markers are not always informative. Therefore, in situations where single-cell direct mutation testing is not practical and intragenic markers are uninformative, we contend that closely linked extragenic markers are acceptable alternatives.
Compared with a previously reported hexaplex panel where two out of four extragenic markers are >1 Mb from the F8 gene [21] , all extragenic markers in our panel locate within 0.6 Mb from the F8 gene, thus minimizing misdiagnosis or no diagnosis caused by recombination between the markers and the F8 gene. Using this newly developed panel, the percentage of individuals harboring at least one heterozygous intragenic marker (~80%) and one heterozygous extragenic marker on each side of the F8 gene (~98%) was higher compared with another hexaplex panel (~70% and~86%, respectively) in the Chinese population [13] . The cumulative ability of at least seven markers to be informative in the panel in the Chinese and Caucasian populations is 59.5% and 55.1%, respectively, which is an improvement over the previous heptaplex panel [16] , where only a maximum of seven markers could be informative. Therefore, this new panel improves the odds of identifying markers that are informative for use in standalone indirect linkage analysis, or as a complement to direct mutation detection, in couples wishing to undergo PGD for HEMA. Several reports have demonstrated that multiplex marker PCR is a reliable indirect linkage-based PGD method for cases involving inversion mutations [19] [20] [21] [22] . Hence, this tetradecaplex marker panel, which contains more markers than previously reported panels, is likely to benefit carriers of the intron-1 or intron-22-mediated inversion mutations the most, because direct single-cell mutation detection is not possible and indirect linkage analysis is the only option [19] . Because only a subset of the marker panel will be informative for any given couple, it is in principle only necessary to genotype those markers that are informative for a particular PGD case. The tetradecaplex marker panel developed in this study offers a rapid and straightforward method for identification of informative markers from the DNA of an interested couple, and any affected and/or unaffected children or close relatives. For the actual PGD cycle, primers for uninformative markers can be simply excluded and primers for the mutation site amplicon (if any) can be easily included in a single-tube multiplex-PCR reaction with minimal modification to the tetradecaplex marker panel's PCR conditions, as was the case for the clinical IVF-PGD case described. Alternatively, the ability to amplify the tetradecaplex marker panel from single-cell whole genome amplification (WGA) product (Fig. 5) affords the option of specific mutation detection and full marker panel haplotype analysis in parallel. Successful amplification for all the markers was observed from the WGA product of all 25 single cells of cell line GM16216, with individual marker ADO ranging from 0 to 44%. Based on the ADO rates after WGA, at least five informative markers are recommended to be used to achieve a 99% diagnostic confidence [9] . Because~81.9% of the Chinese and~70% of the Caucasian samples are heterozygous for five or more markers, the tetradecaplex panel should be able to provide sufficient marker redundancy for use with WGA products.
Our HEMA PGD assay adopts a two-step strategy where the first step involves PCR using unlabeled primers, where each forward primer is chimeric and carries one of three different M13 bacteriophage DNA sequences at its 5 0 end. After the PCR, an aliquot of the product is subjected to cycle-labeling using a cocktail of 6-Fam, Hex or Ned labeled primers corresponding to three different bacteriophage M13 sequences. This strategy reduces development costs during the optimization stage, as only unlabeled primers need to be designed and tested during assay optimization. Moreover, for combined mutation detection and multi-marker assays, unlike the previously reported strategy [19] , the unlabeled products from the first-round amplification in our assay require no post-PCR purification before subsequent minisequencing to detect the mutation from the co-amplified mutationsite amplicon. This difference translates into a simpler PGD workflow, shorter turnaround time and reduced opportunities for human error. This strategy has also been reported to improve amplification efficiency in multiplex PCR [5] .
Overall, all 13 STR markers showed reasonably high heterozygosity indices in the Chinese and Caucasian population samples. The marker polymorphisms are similar to those that have been reported earlier [13] . However, it is possible that these markers may have different ability to provide information in other ethnic groups. In fact, the heterozygosities of some markers are different between the Chinese and Caucasian populations. In addition, some markers in the panel have also been shown to have different allele distributions and heterozygosity values in some western populations [16, [27] [28] [29] . Compared with existing panels, however, the greater number of markers in our panel and the presence of the AMELX/Y dimorphism for gender determination, simplifies and greatly increases the probability of identifying informative markers in each couple interested in HEMA PGD. The strategy of amplifying only fully informative markers and AMELX/Y, with or without a mutation-site amplicon, coupled with the versatility of performing the assay either directly from single cells or after whole genome amplification with minimal assay modification, provides practical solutions for both standalone linkage-based and combined mutation detection and linkage-based HEMA PGD. Addendum S. S. Chong conceptualized and coordinated the project and experiment design, and revised the manuscript. M. Zhao conducted the experiments, data analysis and interpretation, and wrote the manuscript. M. Chen verified the data and revised the manuscript. J. Mathew performed the IVF embryology and embryo biopsies, and reviewed and approved the manuscript. P. C. Wong coordinated patient care, IVF/ICSI and embryo transfer procedures, and reviewed and approved the manuscript. F. S. H. Cheah and A. S. C. Tan conducted the PGD test and revised the manuscript.
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